A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

828

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus I

Interventions

DRUG: GSK1349572 (dolutegravir)
DRUG: raltegravir
OTHER: GSK1349572 Placebo
OTHER: ABC/3TC
OTHER: TDF/FTC
OTHER: raltegravir Placebo

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]